NEJM January 12, 2021
With Jeremy Levin, DPhil, MB BChir, Evelyne Bischof, MD, MPH & Edward Prewitt, MPP

The pharma industry came together under extraordinary circumstances to develop a vaccine for Covid-19. Biotech and AI will play a major role in what’s to come next.

Summary

Jeremy Levin, CEO of Ovid Therapeutics and Chairman of the Biotechnology Innovation Organization, and Evelyne Bischof, Associate Professor at the Shanghai University School of Medicine and Health Sciences and a researcher at University Hospital in Basel, Switzerland, discuss the complexity of vaccine development for Covid-19, and what it can teach us for the future of vaccines, both as clinicians and patients.

Edward Prewitt, MPP, Editorial Director for NEJM Catalyst, interviews Jeremy Levin, CEO of Ovid Therapeutics...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Interview / Q&A, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Public Health / COVID, Trends
BMS plans $1.5B in cuts through '25, with 2000-plus layoffs
Big Pharma's ROI for drug R&D saw 'welcome' rebound in 2023: report
STAT+: Why a British hospital, and not a drugmaker, is trying to get a rare disease therapy approved
STAT+: Profiting from ‘legal’ insider trading isn’t always easy
Regeneron expands in gene editing with Mammoth deal

Share This Article